vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 target price for the company.

vTv Therapeutics Stock Performance

Shares of VTVT stock traded up $0.94 during mid-day trading on Wednesday, reaching $16.66. 3,822 shares of the company’s stock traded hands, compared to its average volume of 7,960. The firm has a market capitalization of $53.15 million, a PE ratio of -3.68 and a beta of 0.73. vTv Therapeutics has a 12 month low of $8.10 and a 12 month high of $30.99. The firm has a 50 day moving average price of $14.81 and a two-hundred day moving average price of $14.95.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC acquired a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned 5.92% of vTv Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.